|
Report Date : |
12.05.2012 |
IDENTIFICATION DETAILS
|
Name : |
CHEMIPHARM PHARMACEUTICAL INDUSTRIES SAE |
|
|
|
|
Registered Office : |
6th
Industrial Zone, Plot 1/2/3, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Year of Establishment : |
1990 |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturer of chemical
products, specialising in human pharmaceuticals |
|
|
|
|
No. of Employees : |
150 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Egypt |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company Name : CHEMIPHARM PHARMACEUTICAL INDUSTRIES SAE
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : 1990
Issued Capital : £E 40,000,000
Paid up Capital : £E 40,000,000
Total Workforce : 150
Activities :
Manufacture of chemical products, specialising in
human
pharmaceuticals.
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
CHEMIPHARM
PHARMACEUTICAL INDUSTRIES SAE
Registered &
Physical Address
Street : 6th
Industrial Zone, Plot 1/2/3
Area : Giza
Town : 6th
of October City
Country : Egypt
Telephone : (20-2) 38349597
/ 38349598 / 38349599 / 38349590 / 38349591
Facsimile : (20-2) 38349594
Mobile :
(20-10) 1721603
Email : info@chemipharm.com.eg
Premises
Subject operates
from a large suite of offices and a factory that are owned and located in the
Industrial Area of the 6th of October City.
Branch Office (s)
Location Description
·
13 Ahmed Orabi Street Sales
Office
Mohandessin,
Giza
Cairo
Tel: (20-2)
33474875 / 33470549
Fax: (20-2)
33474506
Name Position
·
Karim Gamal Kamel Chairman
·
Rafik Nessim Managing
Director
·
Dr Nassef Hanna Ayoub Director
·
Nazih Dawoud Finance
Manager
·
Mohamed
Hamed Purchasing
Manager
Date of Establishment : 1990
Legal Form :
Egyptian Joint Stock
Company
Issued Capital : £E 40,000,000
Paid up Capital : £E 40,000,000
Name of Shareholder
(s)
·
Karim Gamal Kamel
·
Rafik Nessim
·
Dr Nassef Hanna Ayoub
·
Chemipharm
Ltd
13
Ahmed Orabi Street
Mohandessin, Giza
Cairo
Tel: (20-2)
33470549 / 33474875 / 33029560 / 33459186
Fax: (20-2) 33474506
Activities: Engaged in the
manufacture of chemical products, specialising in human pharmaceuticals.
Import
Countries: United States of
America, United Kingdom and Germany.
Agencies Held:
·
Nycomed Germany
·
Heinen Germany
·
Aesculapius Italy
·
ABC Italy
·
Sarong Italy
·
CFM Italy
·
Cosmec Italy
·
Newman United Kingdom
·
Stiefel United Kingdom
·
P&G United
States of America
·
Laboratories
Servier France
·
Pharco Egypt
Brand Names: CHEMIPHARM
Operating Trend: Steady
Subject has a
workforce of 150 employees.
Financial
highlights provided by local sources are given below:
Currency: Egyptian
Pounds (£E)
Year
Ending 31/12/10: Year
Ending 31/12/11:
Total Sales £E 47,350,000 £E 51,000,000
Local sources
consider subject’s financial condition to be Fair.
The above financial
figures are based on estimations by our local sources.
·
Egyptian
American Bank
4 & 6 Hassan Sabri
Zamalek
PO Box: 1825
Cairo
Tel: (20-2) 33416150
Fax: (20-2) 33420265
·
National
Societe Generale Bank
5 Champollion Street
Cairo
Tel: (20-2) 27707777
Fax: (20-2) 27707799
No complaints
regarding subject’s payments have been reported.
Local sources report
that payment obligations are met in a generally timely manner and the operating
history is clear. As such the company is deemed a fair trade risk and the above
credit figure is considered to be within subject’s financial means.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.64 |
|
UK Pound |
1 |
Rs.86.42 |
|
Euro |
1 |
Rs.69.29 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.